Solid Biosciences Initiates Phase 3 Clinical Trial of SGT-003 Gene Therapy (IMPACT DUCHENNE) in Ambulant Males The phase 3 study (NCT07160634) of the SGT-003 gene therapy developed by Solid Biosciences is expected to begin in October 2025 and be completed in January 2029. The SGT-003 Phase 3 study will include 80 ambulant males, moreover the study locations have not yet been shared.

Solid Biosciences Initiates Phase 3 Clinical Trial of SGT-003 Gene Therapy (IMPACT DUCHENNE) in Ambulant Males

#dmd #duchenne #sgt003 #genetherapy #clinicaltrials

👉 Read More: DMDWarrioR.com

Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy Solid Biosciences shared detailed information about the clinical trials of its SGT-003 Gene Therapy developed for the treatment of Duchenne Muscular Dystrophy. Solid Biosciences shared that four patients have been dosed in the SGT-003 gene therapy clinical trial; it was well tolerated in all patients with no side effects observed; and data from the first three patients could be available in Q1 2025.

Solid Biosciences Releases Information on Clinical Trial for SGT-003 Gene Therapy

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #gene #dna #solidbiosciences #sgt003